Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2

Annals of the Rheumatic Diseases

Volumn 76, Issue 2, 2017, Pages 422-426

  Humbert, Marc ^a,b,c   Coghlan, J Gerry ^d   Ghofrani, Hossein Ardeschir ^e,f   Grimminger, Friedrich ^e   He, Jian Guo ^g   Riemekasten, Gabriela ^h   Vizza, Carmine Dario ⁱ   Boeckenhoff, Annette ^j   Meier, Christian ^j   De Oliveira Pena, Janethe ^k   Denton, Christopher P ^l  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^e JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g PEKING UNION MEDICAL COLLEGE   (China)

^h UNIVERSITY OF LÜBECK   (Germany)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j BAYER PHARMA AG   (Germany)

^k Bayer HealthCare Pharmaceuticals Inc   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Arterial Hypertension; Systemic Lupus Erythematosus; Systemic Sclerosis

Indexed keywords

PLACEBO; RIOCIGUAT; ANTIHYPERTENSIVE AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ANEMIA; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CAUSE OF DEATH; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; FEVER; HEADACHE; HEART INDEX; HEART RIGHT VENTRICLE FAILURE; HEMOPTYSIS; HUMAN; HYPOTENSION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POPULATION RESEARCH; POST HOC ANALYSIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC SCLEROSIS; TREND STUDY; WALKING; AGED; CLINICAL TRIAL; COMPLICATION; HYPERTENSION, PULMONARY; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR RESISTANCE; WALK TEST;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PYRAZOLES; PYRIMIDINES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; VASCULAR RESISTANCE; WALK TEST;

EID: 84979497388     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-209087     Document Type: Article

References (19)

1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015;46:903-75.
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94.
3. Schermuly RT, Ghofrani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8:443-55.
4. Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin 2012;8:413-25.
5. Humbert M, Sitbon O, Ya?ci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36: 549-55.
6. Rhee RL, Gabler NB, Sangani S, et al. Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1111-17.
7. Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the reveal registry. Chest 2014;146:1494-504.
8. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-22.
9. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
10. Dees C, Beyer C, Distler A, et al. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis 2015;74:1621-5.
11. Geschka S, Kretschmer A, Sharkovska Y, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 2011;6:e21853.
12. Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 2011;20:567-76.
13. Sharkovska Y, Kalk P, Lawrenz B, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens 2010;28:1666-75.
14. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013;218:279-313.
15. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40.
16. Ghofrani HA, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016;4:361-71.
17. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132: 425-34.
18. Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008;67:1222-8.
19. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010;138:1383-94.